The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 17, 2020
Filed:
Mar. 31, 2016
Applicant:
The General Hospital Corporation, Boston, MA (US);
Inventors:
Raul Mostoslavsky, Boston, MA (US);
Sita Kugel, Brookline, MA (US);
Anders M. Naar, Arlington, MA (US);
Assignee:
The General Hospital Corporation, Boston, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/713 (2006.01); C12Q 1/6886 (2018.01); C12N 15/113 (2010.01); C12Q 1/34 (2006.01); G01N 33/574 (2006.01); G01N 33/50 (2006.01);
U.S. Cl.
CPC ...
A61K 31/713 (2013.01); C12N 15/1135 (2013.01); C12Q 1/34 (2013.01); C12Q 1/6886 (2013.01); G01N 33/50 (2013.01); G01N 33/57438 (2013.01); G01N 33/57476 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01); G01N 2333/82 (2013.01); G01N 2333/98 (2013.01);
Abstract
It has been discovered that NAD+-dependent histone deacetylase SIRT6 is critical for suppression of PDAC by controlling the expression of Lin28b, which is a negative regulator of let-7 microRNA. Specifically, SIRT6 loss results in histone hyperacetylation at the Lin28b promoter, Myc recruitment, and pronounced induction of Lin28b and downstream let-7 target genes, HMGA2, IGF2BP1, and IGF2BP3. This invention relates generally to agents and methods of reducing expression or activity of Lin28b to treat (aggressive) PDAC in a subject.